How much is the vasopressin market worth, and how is it expected to expand?
The vasopressin market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.58 billion in 2025 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increased senior population, hospital and healthcare infrastructure development, increased prevalence of autonomic dysreflexia, increased consciousness among medical professionals, and high prevalence of chronic diseases.
The vasopressin market size is expected to see rapid growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to growing prevalence of diabetes insipidus, improvements in medication delivery systems, enhanced knowledge and diagnosis, research and development initiatives, and increasing awareness about diabetes. Major trends in the forecast period include technological developments in manufacturing, innovations in formulations and delivery techniques, personalized approach for multimodal treatment is new therapeutic approach, focus on health and wellness, and personalization and customization.
Get Your Free Sample of The Global Vasopressin Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16207&type=smp
Which industry factors have accelerated the vasopressin market’s expansion?
The growing prevalence of diabetes is expected to propel the growth of the vasopressin market going forward. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood, resulting from the body’s inability to produce or effectively use insulin. The prevalence of diabetes is due to increasing obesity rates, stress and mental health, and genetic factors. Vasopressin is crucial in managing central diabetes insipidus, as it helps restore average water balance and alleviate the symptoms of excessive urination and thirst. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth highlights a concerning trend in this age group. The data reflects a rapid escalation in diabetes prevalence among younger populations. Therefore, the growing prevalence of diabetes is driving the vasopressin market.
What are the primary segments of the vasopressin market?
The vasopressin market covered in this report is segmented –
1) By Product Type: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
2) By Application: Anti-Diuretic Hormone Deficiency, Vasodilatory Shock, Gastrointestinal Bleeding, Ventricular Tachycardia And Fibrillation
3) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Intravenous Injection: Standard Iv Vasopressin Injection, High-Dose Iv Vasopressin Injection, Iv Vasopressin For Sepsis And Shock Treatment, Iv Vasopressin For Post-Operative Care
2) By Intramuscular Injection: Standard Im Vasopressin Injection, Intramuscular Vasopressin For Hormonal Imbalance, Vasopressin Injection For Acute Hemorrhage Control
3) By Subcutaneous Injection: Subcutaneous Vasopressin For Diabetes Insipidus, Vasopressin Injection For Fluid Retention Treatment, Long-Acting Subcutaneous Vasopressin Formulations
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report
Which firms are leading the vasopressin market?
Major companies operating in the vasopressin market are Pfizer Inc., Merck KGaA, Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Inc., Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals Inc., Ferring Pharmaceuticals, Amphastar Pharmaceuticals Inc., Bachem Holding AG, Eagle Pharmaceuticals Inc., Par Pharmaceutical Holdings Inc., Athenex Inc., Soho-Yiming Pharmaceuticals Co. Ltd., Nordic Pharma Inc., Cumberland Pharmaceuticals Inc., Laboratorio ELEA S.A.C.I.F. y A., Fresenius Kabi Canada Ltd., AMOMED Pharma GmbH, BCN Peptides SA, Hainan Zhonghe Pharmaceutical Co. Ltd., Denovo Biopharma LLC
Which market trends are set to define the future of the vasopressin market?
Major companies operating in the vasopressin market are developing innovative products, such as pre-mix ready-to-use (RTU) injection bottles, to enhance convenience, ensure precise dosing, and improve patient safety by reducing the risk of preparation errors and contamination. Pre-mix ready-to-use (RTU) injection bottles are a significant innovation in the pharmaceutical industry, particularly for medications such as vasopressin. For instance, in February 2022, Endo International plc, a US-based pharmaceutical company, launched VASOSTRICT (vasopressin injection, USP) in ready-to-use 100 mL pre-mix bottles, marking the first and only ready-to-use formulation of this medication. This new VASOSTRICT formulation boasts a two-year shelf life, with up to 12 months at room temperature, offering improved inventory management alongside the other benefits of a ready-to-use presentation. It is supplied as a clear, practically colorless solution for intravenous administration. It is available in single-dose vials containing 20 units per mL and in multiple-dose vials containing 200 units per 10 mL (20 units per mL).
Which geographic trends are shaping the vasopressin market, and which region has the highest market share?
North America was the largest region in the vasopressin market in 2024. The regions covered in the vasopressin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Vasopressin Market Report 2025 Offer?
The vasopressin market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Vasopressin, also known as antidiuretic hormone (ADH), is a peptide hormone produced by the hypothalamus and released by the posterior pituitary gland into the bloodstream. It plays a crucial role in regulating the body’s water and blood pressure, maintaining water balance, regulating blood pressure, and responding to stress.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16207
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
